Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New quick MRI could slash prostate cancer scan costs by 30%

NCT ID NCT05046782

First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 29 times

Summary

This study aimed to test an abbreviated MRI method (using restriction spectrum imaging plus T2-weighted images) for detecting prostate cancer, comparing it to the standard multiparametric MRI. The goal was to see if the faster, cheaper scan could find cancer just as well, while avoiding contrast dye and reducing scan time and cost. However, the study was withdrawn before any participants were enrolled, so no results were obtained.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

restriction spectrum imaging (RSI) MRI device

What this could lead to

If successful, this could provide a faster, cheaper, and safer MRI option for prostate cancer detection, reducing scan time and cost by up to 40%.

What could go wrong

The study was withdrawn before enrolling any participants, so no results are available. The approach may not prove as accurate as standard MRI in practice.

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.